{"id":210578,"date":"2026-02-26T16:01:20","date_gmt":"2026-02-26T15:01:20","guid":{"rendered":"https:\/\/efecomunica.efe.com\/?p=210578"},"modified":"2026-02-26T16:14:46","modified_gmt":"2026-02-26T15:14:46","slug":"curium-announces-pharmacokinetics-and-dosimetry-data-for-investigational-lutetium-177-zadavotide-guraxetan-in-metastatic-castration-resistant-prostate-cancer-at-asco-gu-2026","status":"publish","type":"post","link":"https:\/\/efecomunica.efe.com\/en\/curium-announces-pharmacokinetics-and-dosimetry-data-for-investigational-lutetium-177-zadavotide-guraxetan-in-metastatic-castration-resistant-prostate-cancer-at-asco-gu-2026\/","title":{"rendered":"Curium announces Pharmacokinetics and dosimetry data for investigational lutetium-177 zadavotide guraxetan in metastatic castration-resistant prostate cancer at ASCO GU 2026"},"content":{"rendered":"<p>Statement issued by the company (Announcement)<\/p>\n<div>\n<ul>\n<li><strong><em>Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles<\/em><\/strong><\/li>\n<\/ul>\n<\/div>\n<p><strong>Curium<\/strong>, a world leading nuclear medicine company dedicated to using cutting-edge technology and innovative science to personalize diagnoses and treatments for patients with cancer, today announced the first <strong>dosimetry<\/strong> and <strong>pharmacokinetics<\/strong> (PK) data from a substudy of the ongoing pivotal <strong>Phase 3 ECLIPSE clinical trial<\/strong> (NCT05204927).<\/p>\n<p>The <strong>Phase 3 ECLIPSE clinical trial<\/strong> evaluates <strong>lutetium-177<\/strong> (Lu-177) zadavotide guraxetan\u00a0(a proprietary formulation of\u00a0<sup>177<\/sup>Lu-PSMA-I&amp;T), an investigational prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior androgen receptor pathway inhibitor (ARPI). The data will be presented in a poster at the<strong>\u00a0<\/strong>American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) taking place\u00a026-28 February, 2026, in\u00a0San Francisco, California.<\/p>\n<p>The nonrandomized PK\/dosimetry substudy (n=26) was conducted as part of the ECLIPSE trial to evaluate the biodistribution and radiation absorbed dose of Lu-177 zadavotide guraxetan to organs of interest.<\/p>\n<p><strong>Sakir Mutevelic, MD, Curium\u2019s Chief Medical Officer said<\/strong>: \u201cThese data represent the first published dosimetry data for our investigational formulation of Lu-177 zadavotide guraxetan, with projected mean cumulative renal doses remaining low for a six-cycle treatment regimen, thus supporting a protocol amendment to increase from a maximum of four doses to six in the ECLIPSE trial. We will continue to evaluate the ECLIPSE clinical trial data with the goal of bringing this potential therapy to market for those living with mCRPC. This reinforces our long-term vision to treat 80 percent of cancers within the next 10-15 years.\u201d<\/p>\n<p><strong>Frankis Almaguel, MD, PhD, Assistant Professor, Medicine, Hematology\/Oncology, Loma Linda University Health Cancer Center, and presenting author said<\/strong>: \u201cThese data reinforce the clinical utility of using dosimetry data to inform clinical trial protocol design, as well as identify organs at highest risk of radiation exposure.\u201d<\/p>\n<p>A poster, <em>Pharmacokinetics and Dosimetry of Lutetium Lu 177 Zadavotide Guraxetan in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results From the ECLIPSE Sub-study (Abstract #174),<\/em> will be presented on <strong>Thursday, 26 February in Poster Session A: Prostate Cancer<\/strong>. The abstract is available <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jXF5TIwUKvOALhxlxd1zsO7WGprn_Y61fXZNNEklLOekLQ3vGDopWmQ7hZvdx5gpSn0D_oX3VOZ1s4h87QncYuqQp3TzFBlIW3r_Hh3VTDOY5IRVI2glk2VtrUM37MuN\" target=\"_blank\" rel=\"noopener\"><u>here<\/u><\/a>.<\/p>\n<p>ASCO GU attendees can learn more about Curium by <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Q4-kv-t9IQJ8nJNR7PfGyy4pzfVAzugezmXIePAXpnhH3nCERE5v0X5d9_Ot4XKPw0F2-i5NvQgNlWj06PwSWA-8LgUsWJtsLvCxg6m07r_qShz4099iUBGRO1YvPcXDGhCcxs_7Vh4OYrRk1B1sgHx5DRwLWUOD0BZkIp3LryKz-OrWFclrbEpKm-DBiFp8P7FRRati4yHOMW77cguSFNUQHbx97AJ8KvHwN3hrhPNx5EVLodJpGPK2JRmyd2W0Bnzq51x42yeuZbRhdTTkgniB1PU2kbo_BV3KwpzANF6smBP_3elNs7S2cgRFm4_Ct8xJwPTkfNVOQ_KPOYkv3uvUk5Fnfze2qrks2uYAZibsQn-DPkGIUS9Q94i5Yky8WyJ9__2kSzPCYK-hP_iM-oESGIVJLLktSOyYKNI3-UcZ_JhNNpj3Ql8UmByh2_Tk\" target=\"_blank\" rel=\"noopener\">visiting booth 11<\/a> during the symposium.<\/p>\n<h2>About Curium<\/h2>\n<p>Curium is a world leading global radiopharmaceutical company with proven expertise in the development, manufacturing and supply of radiopharmaceuticals that transform the way cancer is diagnosed and treated. Headquartered in Boston with offices around the world, Curium\u2019s mission is to find new and better ways to diagnose and treat cancer.<\/p>\n<p>With a global footprint that extends to more than 70 countries, a skilled and dedicated team of over 3,000 employees, and four manufacturing sites, Curium is uniquely qualified to meet the significant supply and distribution of established products that underlie success in the radiopharmaceuticals market. Curium\u2019s global leadership is embodied in a diverse and extensive portfolio of over 45 products, that advance patient care for a wide range of cancers.<\/p>\n<p>Curium\u2019s pioneering legacy in nuclear medicine is the foundation of the company\u2019s dedication to innovation and portfolio expansion to cancer therapeutics, particularly in neuroendocrine tumors and with a late-stage pipeline exploring opportunities in prostate cancer.<\/p>\n<p>To learn more, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JGS_ymYjNrCnp6aVBB2Z63KqXaFHIWbt0uw53ce6Xc2Unz9KtXyQ5fZ3nLNybQEG9wZwTTWb4s3vhpuNKuvzmP7ClhXNIvjm_63quZXqaak=\" target=\"_blank\" rel=\"noopener\">www.curiumpharma.com<\/a>.<\/p>\n<pre><strong>Inquiries:<\/strong>\r\n\r\nCamilla Campbell\r\nVP, Head of Global Communications\r\n<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=79T8q1oG2WY_iIFAJ3cHAHq1zGA7wHU0LoJeohkzJ7p0sJTcfW0vCkar_C-FbpJce4N7HcQ8sgoa1tBnQLegVdJmo-jgc8gzACyYSapnOze4gmD3AgL3pXxssZ9khpqUmfV-X4JN_BnKDzqh5J0rhQ==\" target=\"_blank\" rel=\"noopener\">communications@curiumpharma.com<\/a><\/pre>\n<p><em>AGENCIA EFE S.A.U.,S.M.E. shall not be liable for any information contained in this message and assumes no responsibility towards third parties in relation to its contents, being expressly exempt from any liability that the author may have in relation to the information in question. Agencia EFE reserves the right to distribute the press release on the news wire, or to publish it on EFE Comunica.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Statement issued by the company (Announcement) Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles [&hellip;]<\/p>\n","protected":false},"author":198164071,"featured_media":48434,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[125518],"tags":[],"class_list":["post-210578","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Curium announces Pharmacokinetics<\/title>\n<meta name=\"description\" content=\"Curium announced the first dosimetry and pharmacokinetics (PK) data from a substudy of the ongoing pivotal Phase 3 ECLIPSE clinical trial.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/efecomunica.efe.com\/en\/curium-announces-pharmacokinetics-and-dosimetry-data-for-investigational-lutetium-177-zadavotide-guraxetan-in-metastatic-castration-resistant-prostate-cancer-at-asco-gu-2026\/\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Curium announces Pharmacokinetics","description":"Curium announced the first dosimetry and pharmacokinetics (PK) data from a substudy of the ongoing pivotal Phase 3 ECLIPSE clinical trial.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/efecomunica.efe.com\/en\/curium-announces-pharmacokinetics-and-dosimetry-data-for-investigational-lutetium-177-zadavotide-guraxetan-in-metastatic-castration-resistant-prostate-cancer-at-asco-gu-2026\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/efecomunica.efe.com\/en\/curium-announces-pharmacokinetics-and-dosimetry-data-for-investigational-lutetium-177-zadavotide-guraxetan-in-metastatic-castration-resistant-prostate-cancer-at-asco-gu-2026\/#article","isPartOf":{"@id":"https:\/\/efecomunica.efe.com\/en\/curium-announces-pharmacokinetics-and-dosimetry-data-for-investigational-lutetium-177-zadavotide-guraxetan-in-metastatic-castration-resistant-prostate-cancer-at-asco-gu-2026\/"},"author":{"name":"EFE","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/person\/38c335f1ce4cd42430576ef5499343b8"},"headline":"Curium announces Pharmacokinetics and dosimetry data for investigational lutetium-177 zadavotide guraxetan in metastatic castration-resistant prostate cancer at ASCO GU 2026","datePublished":"2026-02-26T15:01:20+00:00","dateModified":"2026-02-26T15:14:46+00:00","mainEntityOfPage":{"@id":"https:\/\/efecomunica.efe.com\/en\/curium-announces-pharmacokinetics-and-dosimetry-data-for-investigational-lutetium-177-zadavotide-guraxetan-in-metastatic-castration-resistant-prostate-cancer-at-asco-gu-2026\/"},"wordCount":630,"publisher":{"@id":"https:\/\/efecomunica.efe.com\/#organization"},"image":{"@id":"https:\/\/efecomunica.efe.com\/en\/curium-announces-pharmacokinetics-and-dosimetry-data-for-investigational-lutetium-177-zadavotide-guraxetan-in-metastatic-castration-resistant-prostate-cancer-at-asco-gu-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","articleSection":["Globenewswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/efecomunica.efe.com\/en\/curium-announces-pharmacokinetics-and-dosimetry-data-for-investigational-lutetium-177-zadavotide-guraxetan-in-metastatic-castration-resistant-prostate-cancer-at-asco-gu-2026\/","url":"https:\/\/efecomunica.efe.com\/en\/curium-announces-pharmacokinetics-and-dosimetry-data-for-investigational-lutetium-177-zadavotide-guraxetan-in-metastatic-castration-resistant-prostate-cancer-at-asco-gu-2026\/","name":"Curium announces Pharmacokinetics","isPartOf":{"@id":"https:\/\/efecomunica.efe.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/efecomunica.efe.com\/en\/curium-announces-pharmacokinetics-and-dosimetry-data-for-investigational-lutetium-177-zadavotide-guraxetan-in-metastatic-castration-resistant-prostate-cancer-at-asco-gu-2026\/#primaryimage"},"image":{"@id":"https:\/\/efecomunica.efe.com\/en\/curium-announces-pharmacokinetics-and-dosimetry-data-for-investigational-lutetium-177-zadavotide-guraxetan-in-metastatic-castration-resistant-prostate-cancer-at-asco-gu-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","datePublished":"2026-02-26T15:01:20+00:00","dateModified":"2026-02-26T15:14:46+00:00","description":"Curium announced the first dosimetry and pharmacokinetics (PK) data from a substudy of the ongoing pivotal Phase 3 ECLIPSE clinical trial.","breadcrumb":{"@id":"https:\/\/efecomunica.efe.com\/en\/curium-announces-pharmacokinetics-and-dosimetry-data-for-investigational-lutetium-177-zadavotide-guraxetan-in-metastatic-castration-resistant-prostate-cancer-at-asco-gu-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/efecomunica.efe.com\/en\/curium-announces-pharmacokinetics-and-dosimetry-data-for-investigational-lutetium-177-zadavotide-guraxetan-in-metastatic-castration-resistant-prostate-cancer-at-asco-gu-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/efecomunica.efe.com\/en\/curium-announces-pharmacokinetics-and-dosimetry-data-for-investigational-lutetium-177-zadavotide-guraxetan-in-metastatic-castration-resistant-prostate-cancer-at-asco-gu-2026\/#primaryimage","url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","contentUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","width":1200,"height":650,"caption":"El \u00edndice Moneyball de Squawka clasifica a los clubes de la Premier League tomando en cuenta las \u00faltimas cinco temporadas (incluida la 2025\/26)."},{"@type":"BreadcrumbList","@id":"https:\/\/efecomunica.efe.com\/en\/curium-announces-pharmacokinetics-and-dosimetry-data-for-investigational-lutetium-177-zadavotide-guraxetan-in-metastatic-castration-resistant-prostate-cancer-at-asco-gu-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/efecomunica.efe.com\/"},{"@type":"ListItem","position":2,"name":"Curium announces Pharmacokinetics and dosimetry data for investigational lutetium-177 zadavotide guraxetan in metastatic castration-resistant prostate cancer at ASCO GU 2026"}]},{"@type":"WebSite","@id":"https:\/\/efecomunica.efe.com\/#website","url":"https:\/\/efecomunica.efe.com\/","name":"EFE Comunica","description":"Contenidos para empresas","publisher":{"@id":"https:\/\/efecomunica.efe.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/efecomunica.efe.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/efecomunica.efe.com\/#organization","name":"EFE Comunica","url":"https:\/\/efecomunica.efe.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/logo\/image\/","url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2020\/12\/Logo-EFE-Comunica_png.png","contentUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2020\/12\/Logo-EFE-Comunica_png.png","width":1080,"height":486,"caption":"EFE Comunica"},"image":{"@id":"https:\/\/efecomunica.efe.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/EFEComunicaAgenciaEFE","https:\/\/x.com\/EFEcomunica","https:\/\/www.linkedin.com\/showcase\/efecomunica"]},{"@type":"Person","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/person\/38c335f1ce4cd42430576ef5499343b8","name":"EFE","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","caption":"EFE"},"sameAs":["http:\/\/efe.com"],"url":"https:\/\/efecomunica.efe.com\/en\/author\/efedesarrollo\/"}]}},"jetpack_featured_media_url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","jetpack_likes_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pcEg1r-SMq","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/210578","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/users\/198164071"}],"replies":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/comments?post=210578"}],"version-history":[{"count":4,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/210578\/revisions"}],"predecessor-version":[{"id":210589,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/210578\/revisions\/210589"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/media\/48434"}],"wp:attachment":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/media?parent=210578"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/categories?post=210578"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/tags?post=210578"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}